01 May 2024

Cambridge, UK: Intertek, a leading Total Quality Assurance provider to industries worldwide, is pleased to announce that the Academy of Pharmaceutical Sciences (APS), will join the third Annual Inhaled and Nasal Biologic/DNA Forum 2024 as Conference Partner.

The independent event, hosted by Intertek, is the industry’s first dedicated forum on inhaled and nasal biologics or DNA medicine development and attracts delegates from around the world. This year’s event will take place from 26-27 September 2024 in Cambridge, UK, and provides a platform for cross-industry understanding on the evolving area of inhaled and nasal drug development.

The APS is a UK-based non-profit professional membership body for pharmaceutical scientists, representing individuals and organisations from around the globe with the aim to promote excellence across research, development and manufacture of medicines in the pharmaceutical sector.

In keeping with the APS’ strategic theme of furthering scientific knowledge, members of the APS board will host a dedicated scientific poster session during the conference. This session is open for researchers and innovators at all levels to share their work in the field of inhaled and nasal biologics or vaccine development.

The event keynote speaker is Dr Jenny Lam, a leading expert in novel respiratory delivery systems at the UCL School of Pharmacy, one of the world’s leading pharmacy schools. Dr Lam will present on the theme of ‘Alternative to LNPs – development of peptide-based RNA delivery systems for pulmonary delivery’. Other esteemed speakers include Prof. Dr. Regina Scherließ from Christian Albrechts University in Kiel, and Dr. Francesca Buttini, Associate Professor at the University of Parma.

Chris Vernall, Intertek Commercial Director, said: “We are delighted that the Academy of Pharmaceutical Sciences is joining the Inhaled and Nasal Biologics/DNA Forum as Conference Partner. The goal of this event has always been to provide a platform for collaboration, learning, and innovation. Partnering with the APS is important to widen the visibility and accessibility of the event for researchers in the area, and to ensure that the conference continues to be independently science-led. The APS has a long history of promoting education and collaboration in the respiratory space, and we are very grateful for their support.’’

Professor Ryan Donnelly, Chair, Academy of Pharmaceutical Sciences, commented: “One of our core goals is to champion innovation and opportunity in pharmaceutical sciences and by supporting the Annual Inhaled and Nasal Biologics/DNA Forum 2024, we aim to support our members by enabling education, conversation and collaboration in this complex and evolving area of drug development.”

Hosting this annual forum highlights Intertek’s commitment to supporting the advance of science and innovation in the field of inhaled and nasal biologics, DNA therapeutics and vaccine development. With a Centre of Excellence for the development of these products at its Cambridge, UK, laboratories, Intertek supports clients around the world to meet milestones for their challenging pharmaceutical development programmes. 

For Media Information

Please contact:
Lorna Kettle
ECA Marketing Director, Intertek Pharmaceutical Services
T: +44 (0) 116 296 1620
E: lorna.kettle@intertek.com

About the 3rd Annual Inhaled and Nasal Biologics/DNA Forum

Registration is now open, and early bird discounts are available until 31 May 2024. For more information, visit the conference website today: https://www.intertek.com/pharmaceutical/events/inhaled-nasal-biologics-dna-forum.

About the Academy of Pharmaceutical Sciences (APS)

The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.  We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.  Pharmaceutical Scientists are experts in the research, development and manufacture of medicines. They have a major role in the regulation of medicines and understanding their use in patients.

The APS is a not-for-profit organisation. We use revenues to champion innovation and opportunity in Pharmaceutical Sciences thereby improving the development and delivery of medicines for the benefit of patients. Our four key strategic themes, which are the foundation of all APS activities, are:

  • Establish and promote the reputation of Pharmaceutical Sciences and Scientists
  • Influence policy
  • Further scientific knowledge
  • Promote careers


About Intertek


Intertek is a leading Total Quality Assurance provider to industries worldwide.

Our network of more than 1,000 laboratories and offices in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers' operations and supply chains.

Intertek is a purpose-led company to Bring Quality, Safety and Sustainability to Life. We provide 24/7 mission-critical quality assurance solutions to our clients to ensure that they can operate with well-functioning supply chains in each of their operations.

Our Customer Promise is: Intertek Total Quality Assurance expertise, delivered consistently, with precision, pace and passion, enabling our customers to power ahead safely.